Paragraph IV Certifications: How Generic Drug Companies Challenge Patents Before Launch
Paragraph IV certifications let generic drug makers challenge brand-name patents before launch, speeding up affordable drug access. This legal tool under the Hatch-Waxman Act has saved U.S. consumers over $2 trillion since 1984.